Takeda Ordered to Pay $2.3 Million in Damages to Actos User
This article is for subscribers only.
Takeda Pharmaceutical Co. was ordered by a jury Thursday to pay more than $2.3 million in damages to a former teacher who blamed the company’s Actos diabetes drug for causing his bladder cancer.
Jurors in state court in Philadelphia deliberated more than eight hours over two days before finding that Osaka, Japan-based Takeda failed to properly warn John Kristufek’s doctors about Actos’s cancer risks. The panel concluded Kristufek deserved more than $300,000 for his medical expenses and $2 million for pain and suffering tied to the cancer diagnosis, his lawyers said.